AgingResearch.NewsJoin free

Trafermin

Trafermin has been studied in 1 paper since 2023: 1 observational study in people. The newest paper, May 2, 2023: “One Year Outcomes and Longitudinal Changes in Voice Improvement With Single High Dose Intracordal Trafermin Injections for Age-Related Vocal Fold Atrophy”.

Intervention

1 paper studies it1 findingUpdated

“Maximum phonation time (MPT), pitch range (PR), Japanese version of voice handicap index (VHI), grade of GRBAS evaluation, and jitter% improved significantly at 1-year post-injection compared to 1-month pre-injection.”
One Year Outcomes and Longitudinal Changes in Voice Improvement With Single High Dose Intracordal Trafermin Injections for Age-Related Vocal Fold AtrophyJournal of voice : official journal of the Voice Foundation2023doi:10.1016/j.jvoice.2023.03.017

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funder: Japan Society for the Promotion of Science
  • Humans1

What did studies of Trafermin find?

1

Studies of Trafermin measured 1 outcome; the most studied are voice function (1 study).

Voice function

upin humans1

1 study

  1. Trafermin improves voice function in humans.

    “Maximum phonation time (MPT), pitch range (PR), Japanese version of voice handicap index (VHI), grade of GRBAS evaluation, and jitter% improved significantly at 1-year post-injection compared to 1-month pre-injection.”

    Human trialage-related vocal fold atrophyvocal cord50ug per side1 yearn = 34

    One Year Outcomes and Longitudinal Changes in Voice Improvement With Single High Dose Intracordal Trafermin Injections for Age-Related Vocal Fold Atrophy

    Journal of voice : official journal of the Voice Foundation

Latest

Related